Form 4: Arrowhead Pharmaceuticals CEO Exercises and Sells Shares Under 10b5-1 Plan

Arrowhead Pharmaceuticals' CEO, Christopher Anzalone, exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan as the options approached their expiration date.

Summary

• Christopher Anzalone, CEO of Arrowhead Pharmaceuticals, exercised non-qualified stock options and sold shares of common stock on March 3rd and 4th, 2025.
• The transactions were executed under a 10b5-1 trading plan adopted by Anzalone.
• On March 3rd, 2025, 166,667 shares were acquired through option exercise at $7.75 per share and then sold at an average price of $18.03.
• On March 4th, 2025, 133,333 shares were acquired through option exercise at $7.75 per share and then sold at a weighted average price of $17.02, with prices ranging from $16.58 to $17.48.
• Following these transactions, Anzalone directly owns 3,773,802 shares of Arrowhead Pharmaceuticals common stock.
• Anzalone also holds 51,726 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The document is neutral. It simply reports transactions related to stock options and share sales under a pre-existing plan. There is no inherent positive or negative sentiment.

Positives

• The CEO's transactions were conducted under a pre-arranged 10b5-1 trading plan, which is generally viewed as a transparent and compliant practice.

Risks

• Executive stock sales, even under 10b5-1 plans, can sometimes be perceived negatively by investors if not clearly explained.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Management Comments

• The exercise of non-qualified stock options and sale was made as the stock options were approaching their expiration date.
• The shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

Industry Context

Executive stock transactions are common in the pharmaceutical industry and are often part of compensation packages. The use of 10b5-1 plans is a standard practice to avoid accusations of insider trading.

Comparison to Industry Standards

• Executive compensation structures, including stock options, are common across the pharmaceutical industry.
• Companies like Alnylam Pharmaceuticals and Ionis Pharmaceuticals also utilize stock options as part of their executive compensation packages.
• The use of 10b5-1 trading plans is a widespread practice among executives in publicly traded companies to manage their stock sales in a compliant manner.

Stakeholder Impact

• The transactions could have a minor impact on shareholders due to the increased number of shares sold in the market.

Key Dates